<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE339nnn/GSE339493/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE339493</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Interleukin-33 activated group 2 innate lymphoid cells drive type 2 immune dysfunction in endometriosis</name><description>Immune dysfunction is a key contributor to endometriosis (EM) pathophysiology, with a type 2-skewed immune response thought to support EM lesion maintenance and establishment. The alarmin interleukin-33 (IL-33) is elevated in EM patient plasma, peritoneal fluid (PF), and lesions compared to controls, and in an EM mouse model IL-33 drives lesion progression, although exact mechanisms remain unclear. Here we validate that IL-33/ST2 signaling contributes to EM pathophysiology, identifying IL-33/ST2 axis dysregulation in EM lesions compared to control endometrial tissue and characterize PF group 2 innate lymphoid cells (ILC2s) with upregulation of ST2+ in severe stage patients. Using ILC2-deficient mice, we demonstrate that ILC2s are critical for the IL-33-driven inflammatory response in EM. IL-33 treatment in EM-induced ILC2-deficient mice resulted in reduced type 2 effector cytokine production and dysregulated immune infiltration, as well as an altered lesion transcriptional signature compared to ILC2-sufficient controls. Notably, reintroducing ILC2s was insufficient to rescue the IL-33-mediated response; however, we identified ILC2 homing to EM lesions. Finally, we identify ST2 neutralization as a promising therapeutic technique to blunt the IL-33/ILC2 type 2 response in EM.</description><dates><publication>2026/08/03</publication></dates><accession>GSE339493</accession><cross_references><GSM>GSM9896533</GSM><GSM>GSM9896511</GSM><GSM>GSM9896512</GSM><GSM>GSM9896534</GSM><GSM>GSM9896535</GSM><GSM>GSM9896513</GSM><GSM>GSM9896536</GSM><GSM>GSM9896514</GSM><GSM>GSM9896515</GSM><GSM>GSM9896537</GSM><GSM>GSM9896538</GSM><GSM>GSM9896516</GSM><GSM>GSM9896539</GSM><GSM>GSM9896517</GSM><GSM>GSM9896518</GSM><GSM>GSM9896530</GSM><GSM>GSM9896531</GSM><GSM>GSM9896532</GSM><GSM>GSM9896510</GSM><GSM>GSM9896508</GSM><GSM>GSM9896509</GSM><GSM>GSM9896544</GSM><GSM>GSM9896522</GSM><GSM>GSM9896523</GSM><GSM>GSM9896545</GSM><GSM>GSM9896546</GSM><GSM>GSM9896524</GSM><GSM>GSM9896547</GSM><GSM>GSM9896525</GSM><GSM>GSM9896526</GSM><GSM>GSM9896548</GSM><GSM>GSM9896527</GSM><GSM>GSM9896528</GSM><GSM>GSM9896529</GSM><GSM>GSM9896540</GSM><GSM>GSM9896541</GSM><GSM>GSM9896520</GSM><GSM>GSM9896542</GSM><GSM>GSM9896543</GSM><GSM>GSM9896521</GSM><GSM>GSM9896519</GSM><GPL>24247</GPL><GSE>339493</GSE><taxon>Mus musculus</taxon></cross_references></HashMap>